These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33802438)

  • 1. Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer.
    Mezi S; Botticelli A; Pomati G; Cerbelli B; Scagnoli S; Amirhassankhani S; d'Amati G; Marchetti P
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition.
    Markiewicz A; Topa J; Popęda M; Szade J; Skokowski J; Wełnicka-Jaśkiewicz M; Żaczek A
    Acta Biochim Pol; 2021 Aug; 68(3):385-392. PubMed ID: 34432400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
    Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
    J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard of care and promising new agents for triple negative metastatic breast cancer.
    Mancini P; Angeloni A; Risi E; Orsi E; Mezi S
    Cancers (Basel); 2014 Oct; 6(4):2187-223. PubMed ID: 25347122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer.
    Naeimzadeh Y; Heidari Z; Razban V; Khajeh S
    Curr Mol Pharmacol; 2024; 17(1):e18761429263841. PubMed ID: 37916633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
    Vishnubalaji R; Alajez NM
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer.
    Liu Y; Fang Y; Bao L; Wu F; Wang S; Hao S
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNAs in the prognosis of triple-negative breast cancer: A review.
    Anilkumar KV; Rema LP; John MC; Vanesa John T; George A
    Life Sci; 2023 Nov; 333():122183. PubMed ID: 37858714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
    Li B; Huang L; Ruan J
    Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
    Yeh SJ; Hsu BJ; Chen BS
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
    Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M
    Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
    BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatic miRNA-mRNAs Analysis Revels to miR-934 as a Potential Regulator of the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer.
    Contreras-Rodríguez JA; Puente-Rivera J; Córdova-Esparza DM; Nuñez-Olvera SI; Silva-Cázares MB
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Interaction to Intervention: How Mesenchymal Stem Cells Affect and Target Triple-Negative Breast Cancer.
    Wu Y; Shum HCE; Wu K; Vadgama J
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Lox in triple-negative breast cancer.
    Leo C; Cotic C; Pomp V; Fink D; Varga Z
    Ann Diagn Pathol; 2018 Jun; 34():98-102. PubMed ID: 29661738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer.
    Shettigar A; Salunke R; Modi D; Mukherjee N
    Int Immunopharmacol; 2023 Jun; 119():110250. PubMed ID: 37163922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
    Cao T; Huang M; Huang X; Tang T
    PeerJ; 2024; 12():e16935. PubMed ID: 38435998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.